天堂√在线中文最新版,欧美久久在线,久草精品在线

Pfizer 2024 Financial Report Financial statements Pfizer's 2024 financial report highlights a 7% revenue increase, with strong performance from oncology, migraine drugs, and ADCs. The company also expects significant advancements in 2025 across various therapeutic areas.
Samsung Biologics 2024 Q4 Financial Report Financial statements Samsung Biologics reports record-high revenue and orders for 2024, driven by success at Plant 4. The company secured its largest-ever contract, solidifying its position as a top global CDMO partner.
Johnson & Johnson 2024 Q4 Financial Report Financial statements Johnson & Johnson's 2024 financial report reveals a 4.3% revenue increase, with Daratumumab (Darzalex) reaching $11.67B and Carvykti seeing a 92.7% growth. Key oncology, immunology, and neuroscience advancements also highlighted.
Chemical Giants' Latest Performance Reports Financial statements Discover the latest Q3 2024 earnings reports from major chemical giants like Evonik, DuPont, Huntsman, and more. Find key financial highlights, forecasts, and business updates from industry leaders.
Gilead's Q3 Performance: Pipeline Cuts and CAR-T Sales Success Financial statements Gilead released Q3 Performance: Revenue for the first three quarters of 2024 was US$21.185 billion, a year-on-year increase of 6%; total revenue for Q3 2024 was US$7.545 billion, a year-on-year increase of 5%, mainly due to sales growth of the AIDS drug Veklury and oncology and liver disease drugs.
Revenue of $640M! First Global TIL Cell Therapy's Q3 Performance Financial statements On November 7, local time, Iovance, a global leader in TIL (Tumor Infiltrating Lymphocytes) cell drug development, released its Q3 financial results. TIL therapy, Amtagvi? (Lifileucel), continues strongly, with total product revenue reaching $58.6M (approximately ￥640 million) in Q3 2024.
Novo Nordisk 2024 Q3 Financial statements Novo Nordisk's Q3 2024 results show impressive growth, with Semaglutide sales reaching $20.6B. GLP-1 drugs, including Ozempic and Rybelsus, drive significant revenue, especially in China. The company projects continued growth in 2024.
Eli Lilly Q3 2024 Financial statements Financial statements Eli Lilly's Q3 2024 report reveals strong growth with $31.5 billion in revenue, driven by $11 billion in sales from tirzepatide products Mounjaro and Zepbound, Mounjaro's sales doubled. With an expanded production capacity, Eli Lilly projecting a market potential of $150 billion by 2030.
AbbVie Q3 2024 Financial statements Financial statements In Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
Takeda Q2 2024 Financial Results Financial statements Takeda's Q2 2024 results show strong performance with total revenue of 2.384 trillion yen and upgraded full-year forecasts. Key highlights include Fruquintinib's overseas sales reaching 23.1 billion yen, driven by significant growth in the U.S. market.

< Pre 1...9 10 111213 14 15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a